Investors

Press Releases

Press Releases

November 12, 2019
Allakos Reports Third Quarter 2019 Financial Results
REDWOOD CITY, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the third quarter ended September 30, 2019.
August 6, 2019
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the upsizing and pricing of its previously announced underwritten public
August 5, 2019
Allakos Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $200
August 5, 2019
Allakos Reports Second Quarter 2019 Financial Results
REDWOOD CITY, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the second quarter ended June 30, 2019.
May 8, 2019
Allakos Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019.
Displaying 1 - 10 of 14


(Common Stock)


April 12, 2024 11:23 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.